Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Spero Therapeutics Inc (NQ: SPRO )

17.75 USD +0.54 (+3.14%)
Official Closing Price Updated: 6:27 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Spero Therapeutics Inc

< Previous 1 2 3 Next >
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
From GlobeNewswire News Releases
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
From GlobeNewswire News Releases
Spero Therapeutics Added to the NASDAQ Biotechnology Index
From GlobeNewswire News Releases
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
From GlobeNewswire News Releases
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization 
From GlobeNewswire News Releases
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020
From GlobeNewswire News Releases
Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update
From GlobeNewswire News Releases
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
From GlobeNewswire News Releases
Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020
15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 
From GlobeNewswire News Releases
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections
From GlobeNewswire News Releases
Spero Therapeutics to Present at Investor Conferences in September
From GlobeNewswire News Releases
Spero Therapeutics Announces Pricing of Securities Offering
From GlobeNewswire News Releases
Spero Therapeutics Announces Proposed Public Offering
From GlobeNewswire News Releases
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
From GlobeNewswire News Releases
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720
From GlobeNewswire News Releases
Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update
From GlobeNewswire News Releases
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
From GlobeNewswire News Releases
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
From NewMediaWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO
From GlobeNewswire News Releases
Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
From NewMediaWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO
From GlobeNewswire News Releases
SPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
From NewMediaWire
Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
From GlobeNewswire News Releases
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
SPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.